Accessing BPC-157 in Canada Canadian researchers and individuals interested in BPC-157 navigate a regulatory landscape that differs from both complete prohibition and full pharmaceutical approval
Actual medications may vary depending on the prescribing provider, pharmacy, and applicable regulations
Effective April 22, 2026, BPC-157 was removed from Category 2 (the bulks substances list flagged as raising significant safety concerns)
Get Started Schedule a consultation with our medical team to learn if GHK/Epithalon dual-action therapy is right for your aesthetic and longevity goals
(2019), administering DSIP to rodents showed improvement in non-rapid eye movement (NREM) sleep, particularly in deep slow-wave sleep (SWS)
This article explains general peptide reconstitution principles, UK regulatory status, and critical safety considerations it does not constitute clinical advice or endorse self-administration